Yunnan Baiyao Group Co., Ltd.
Yunnan Baiyao was created in 1902, combining brand, product and company name, and is a representative of the innovative power of Chinese time-honored brands. Yunnan Baiyao Special Factory was established in 1970, listed in 1993, and re-engineered modern enterprises in 1999. Migrant reform and overall listing were completed from 2016 to 2019, laying a solid institutional and mechanism foundation for the company to create another century of glory. The company is committed to bringing traditional Chinese medicine into modern life, and has developed from a bottle of powder to one of the leaders in my country's big health industry covering four major sectors: medicines, personal care and health products, Chinese medicinal materials resources and medical flow. The products have 36 categories and 390 varieties, and 11 products have sold hundreds of millions of dollars in a single product. Toothpaste, aerosol, bandages, paste patches, etc. are the top products in the country in related categories. The company adopts the business unit system to develop existing businesses, which are divided into medicines, health products, traditional Chinese medicine resources business departments and Yunnan Pharmaceutical Co., Ltd. (responsible for pharmaceutical abortion business). Each business department takes responsibility and works together, and its main business has reached the national advanced level. Deploy factories in Kunming, Dali, Wenshan, Lijiang, Wuding, Wuxi, Jiangsu, Hefei, Anhui, etc., with sales channels covering the whole country. The company regards protecting life and health as its corporate mission and is committed to becoming a leading provider of comprehensive medical and health solutions. Based on the above mission and vision, Yunnan Baiyao, on the basis of consolidating its existing business, determined the strategic goal of achieving "1+4+1" (Traditional medicine + oral, skin, bone injuries, female care + digitalization), and optimized the industry and R&D. The system has completed its layout in Beijing, Shanghai, Hong Kong, Hainan and South Korea, becoming an important strategic support for Baiyao to gather global resources and serve the Chinese market, and conducts basic research, commercial development, product innovation and marketing. The company carries out the "six major innovations" methods such as technological innovation, business model innovation, product innovation, organizational innovation, talent innovation and brand renewal, adopts the "four-wheel drive" model of marketing, innovation, capital and digitalization, and strives to achieve significant growth as soon as possible. and breakthroughs, and contribute to the leap in the development of China's pharmaceutical and health industry.
Yunnan Baiyao Group Co., Ltd.
Yunnan Baiyao was created in 1902, combining brand, product and company name, and is a representative of the innovative power of Chinese time-honored brands. Yunnan Baiyao Special Factory was established in 1970, listed in 1993, and re-engineered modern enterprises in 1999. Migrant reform and overall listing were completed from 2016 to 2019, laying a solid institutional and mechanism foundation for the company to create another century of glory. The company is committed to bringing traditional Chinese medicine into modern life, and has developed from a bottle of powder to one of the leaders in my country's big health industry covering four major sectors: medicines, personal care and health products, Chinese medicinal materials resources and medical flow. The products have 36 categories and 390 varieties, and 11 products have sold hundreds of millions of dollars in a single product. Toothpaste, aerosol, bandages, paste patches, etc. are the top products in the country in related categories. The company adopts the business unit system to develop existing businesses, which are divided into medicines, health products, traditional Chinese medicine resources business departments and Yunnan Pharmaceutical Co., Ltd. (responsible for pharmaceutical abortion business). Each business department takes responsibility and works together, and its main business has reached the national advanced level. Deploy factories in Kunming, Dali, Wenshan, Lijiang, Wuding, Wuxi, Jiangsu, Hefei, Anhui, etc., with sales channels covering the whole country. The company regards protecting life and health as its corporate mission and is committed to becoming a leading provider of comprehensive medical and health solutions. Based on the above mission and vision, Yunnan Baiyao, on the basis of consolidating its existing business, determined the strategic goal of achieving "1+4+1" (Traditional medicine + oral, skin, bone injuries, female care + digitalization), and optimized the industry and R&D. The system has completed its layout in Beijing, Shanghai, Hong Kong, Hainan and South Korea, becoming an important strategic support for Baiyao to gather global resources and serve the Chinese market, and conducts basic research, commercial development, product innovation and marketing. The company carries out the "six major innovations" methods such as technological innovation, business model innovation, product innovation, organizational innovation, talent innovation and brand renewal, adopts the "four-wheel drive" model of marketing, innovation, capital and digitalization, and strives to achieve significant growth as soon as possible. and breakthroughs, and contribute to the leap in the development of China's pharmaceutical and health industry.
Xiuzheng Pharmaceutical Group Co., Ltd.
Xiuzheng Group was founded by Chairman Xiu Laigui in May 1995. It is a large modern private pharmaceutical enterprise integrating scientific research, production and marketing of patent medicines, chemical medicines, and biopharmaceuticals, pharmaceutical chain operations, and standard cultivation of traditional Chinese medicinal materials. Through secondary development, the group has cultivated more than a dozen major varieties such as Feining, Empty Hydrochloride, Liuwei Dihuang, Neiyaku Kang, Yiqi and Blood Health, etc.; it has integrated the transformation of scientific and technological management, innovative drug research, and new technological achievements into a domestic one. The scientific research system has more than 300 technical experts, more than 700 authorized patents, and won 7 national scientific and technological progress awards. There are nationally certified enterprise technology centers, national engineering laboratories for quality control technology in traditional Chinese medicine, postdoctoral research workstations, and key laboratories for key engineering technology in traditional Chinese medicine standardization. Correcting health is an important support for the big health strategy and an important wing for the revision of the "professional development, two wings flying together" strategy. Starting from 2021, we will focus on health product research and development and health management. Headquarters are located in Changchun, Jilin and Hangzhou, Zhejiang, respectively, including 8 industrial bases, covering an area of more than 1,000 mu. Currently, six industrial bases in Changchun Shuangyang, Jilin Panshi, Baishan Jingyu, Shandong Weifang, Anhui Bozhou and Hangzhou Qiandaohu have been put into production. , sales channels cover multiple channels such as e-commerce, new retail, maternal and infant, pharmacies and supermarket third terminals. Currently, there are about 670 varieties in production and sales, 404 registered trademarks, and 50 patents. Its well-known products such as Spot Cream, Red Bean and Barley Tea, Xiuyisheng Probiotics, Uer Capsules, Svino Oral Liquid, Glycosammonia Chondroitin, and Youzhi DHA are well-known throughout the country, occupying the leading position in the big health sector and are deeply influenced by Good reviews from consumers. The product line covers a variety of dosage forms such as health foods, nourishing foods, fast-selling foods, alternative teas, health wines, mineral water, functional cosmetics, cosmetics, etc.
Xiuzheng Pharmaceutical Group Co., Ltd.
Xiuzheng Group was founded by Chairman Xiu Laigui in May 1995. It is a large modern private pharmaceutical enterprise integrating scientific research, production and marketing of patent medicines, chemical medicines, and biopharmaceuticals, pharmaceutical chain operations, and standard cultivation of traditional Chinese medicinal materials. Through secondary development, the group has cultivated more than a dozen major varieties such as Feining, Empty Hydrochloride, Liuwei Dihuang, Neiyaku Kang, Yiqi and Blood Health, etc.; it has integrated the transformation of scientific and technological management, innovative drug research, and new technological achievements into a domestic one. The scientific research system has more than 300 technical experts, more than 700 authorized patents, and won 7 national scientific and technological progress awards. There are nationally certified enterprise technology centers, national engineering laboratories for quality control technology in traditional Chinese medicine, postdoctoral research workstations, and key laboratories for key engineering technology in traditional Chinese medicine standardization. Correcting health is an important support for the big health strategy and an important wing for the revision of the "professional development, two wings flying together" strategy. Starting from 2021, we will focus on health product research and development and health management. Headquarters are located in Changchun, Jilin and Hangzhou, Zhejiang, respectively, including 8 industrial bases, covering an area of more than 1,000 mu. Currently, six industrial bases in Changchun Shuangyang, Jilin Panshi, Baishan Jingyu, Shandong Weifang, Anhui Bozhou and Hangzhou Qiandaohu have been put into production. , sales channels cover multiple channels such as e-commerce, new retail, maternal and infant, pharmacies and supermarket third terminals. Currently, there are about 670 varieties in production and sales, 404 registered trademarks, and 50 patents. Its well-known products such as Spot Cream, Red Bean and Barley Tea, Xiuyisheng Probiotics, Uer Capsules, Svino Oral Liquid, Glycosammonia Chondroitin, and Youzhi DHA are well-known throughout the country, occupying the leading position in the big health sector and are deeply influenced by Good reviews from consumers. The product line covers a variety of dosage forms such as health foods, nourishing foods, fast-selling foods, alternative teas, health wines, mineral water, functional cosmetics, cosmetics, etc.
Renhe (Group) Development Co., Ltd.
Renhe Pharmaceutical Co., Ltd. is a listed company listed on the Shenzhen Stock Exchange. The company's stock code is: 000650. The company's predecessor is Jiujiang Chemical Fiber Co., Ltd., which was approved by the Jiangxi Provincial People's Government in 1996. On November 18, 1996 , a company officially listed on the Shenzhen Stock Exchange with the approval of the China Securities Regulatory Commission’s Securities Regulatory Commission (1996) No. 318. In 2006, the company implemented a major asset restructuring, divested its original chemical fiber-related assets, and injected pharmaceutical assets. Through multiple share allocations, transfers, targeted share issuances, etc., the company has become Jiangxi Renhe Pharmaceutical Co., Ltd. and Jiangxi Renhe. China Pharmaceutical Co., Ltd., Jiangxi Renhe Pharmaceutical Co., Ltd., Jiangxi Heli Pharmaceutical Co., Ltd., Jiangxi Kangmei Pharmaceutical Health Products Co., Ltd., Jiangxi Pharmaceutical Durenhe Pharmaceutical Co., Ltd., Jiangxi Tonggu Renhe Pharmaceutical Co., Ltd., Jiangxi Shining Pharmaceutical Modern pharmaceutical production and operation enterprises of many subsidiaries such as Jiangxi Ji'an Sanli Pharmaceutical Co., Ltd., Jiangxi Renhe Pharmaceutical Products Co., Ltd., Jiangxi Pharmaceutical Co., Ltd., Jiangxi Pharmaceutical Co., Ltd., Jiangxi Pharmaceutical City Zhangshu Pharmaceutical Co., Ltd. and other subsidiaries. The company's main business: production and sales of traditional Chinese and Western medicines, raw materials and health-related products, including oral solid preparations, oral liquid preparations, large-volume injections, small-volume injections, topical lotions, liniments, suppositories, ointments and other dosage-form drugs, as well as Health-related products. The company's main products: Renhe Kelik, Youkadan series, Fuyanjie series, Dahuolou capsules, Shining eye drops, Qinghuo capsules, Zhengwei capsules, etc. Business scope is: Chinese medicinal materials planting; medicinal seedling cultivation; carton production and sales; computer software development; design, production, release, and agency of various domestic advertisements; building materials, machinery and equipment, hardware and electrical and electronic products, chemical products, Wholesale and retail of metal materials, cultural and sports office supplies, department stores. (Except for the above projects that have special provisions in the country). The company has established and consolidated a sales network covering 30 provinces, cities and autonomous regions across the country. The company adheres to the purpose of "serving human health", follows the corporate philosophy of "people-oriented and harmony-oriented", and the business philosophy of "benevolence and harmony, and win-win" and promotes the corporate spirit of "integrity and unity and keeping pace with the times". With the historical expectation of revitalizing the country's medical industry, we will go to the world and the future with new horizons and new ideas.
Renhe (Group) Development Co., Ltd.
Renhe Pharmaceutical Co., Ltd. is a listed company listed on the Shenzhen Stock Exchange. The company's stock code is: 000650. The company's predecessor is Jiujiang Chemical Fiber Co., Ltd., which was approved by the Jiangxi Provincial People's Government in 1996. On November 18, 1996 , a company officially listed on the Shenzhen Stock Exchange with the approval of the China Securities Regulatory Commission’s Securities Regulatory Commission (1996) No. 318. In 2006, the company implemented a major asset restructuring, divested its original chemical fiber-related assets, and injected pharmaceutical assets. Through multiple share allocations, transfers, targeted share issuances, etc., the company has become Jiangxi Renhe Pharmaceutical Co., Ltd. and Jiangxi Renhe. China Pharmaceutical Co., Ltd., Jiangxi Renhe Pharmaceutical Co., Ltd., Jiangxi Heli Pharmaceutical Co., Ltd., Jiangxi Kangmei Pharmaceutical Health Products Co., Ltd., Jiangxi Pharmaceutical Durenhe Pharmaceutical Co., Ltd., Jiangxi Tonggu Renhe Pharmaceutical Co., Ltd., Jiangxi Shining Pharmaceutical Modern pharmaceutical production and operation enterprises of many subsidiaries such as Jiangxi Ji'an Sanli Pharmaceutical Co., Ltd., Jiangxi Renhe Pharmaceutical Products Co., Ltd., Jiangxi Pharmaceutical Co., Ltd., Jiangxi Pharmaceutical Co., Ltd., Jiangxi Pharmaceutical City Zhangshu Pharmaceutical Co., Ltd. and other subsidiaries. The company's main business: production and sales of traditional Chinese and Western medicines, raw materials and health-related products, including oral solid preparations, oral liquid preparations, large-volume injections, small-volume injections, topical lotions, liniments, suppositories, ointments and other dosage-form drugs, as well as Health-related products. The company's main products: Renhe Kelik, Youkadan series, Fuyanjie series, Dahuolou capsules, Shining eye drops, Qinghuo capsules, Zhengwei capsules, etc. Business scope is: Chinese medicinal materials planting; medicinal seedling cultivation; carton production and sales; computer software development; design, production, release, and agency of various domestic advertisements; building materials, machinery and equipment, hardware and electrical and electronic products, chemical products, Wholesale and retail of metal materials, cultural and sports office supplies, department stores. (Except for the above projects that have special provisions in the country). The company has established and consolidated a sales network covering 30 provinces, cities and autonomous regions across the country. The company adheres to the purpose of "serving human health", follows the corporate philosophy of "people-oriented and harmony-oriented", and the business philosophy of "benevolence and harmony, and win-win" and promotes the corporate spirit of "integrity and unity and keeping pace with the times". With the historical expectation of revitalizing the country's medical industry, we will go to the world and the future with new horizons and new ideas.
China Resources Pharmaceutical Holdings Co., Ltd.
China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large state-owned pharmaceutical listed company, mainly engaged in the research and development, production, sales and related health services of pharmaceutical products. Up to now, China Resources Sanjiu has been included in the Shenzhen Component Index, CSI 500 and FTSE Russell Index. China Resources Sanjiu was predecessored by Shenzhen Southern Pharmaceutical Factory established in 1985. In 1999, five companies including Sanjiu Enterprise Group and Shenzhen Sanjiu Pharmaceutical Co., Ltd. initiated the establishment of joint-stock companies; on March 9, 2000, it was listed on the Shenzhen Stock Exchange (stock code is 000999); in 2008, Officially entered China Resources Group; in 2010, the company's name was changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd.". China Resources Sanjiu’s main core business is positioned in the fields of CHC health consumer goods and prescription drugs, with a rich product line and a continuous enrichment of varieties. CHC's health consumer products business covers nearly 10 categories including colds, skin, gastrointestinal tract, cough relieving, orthopedics, pediatrics, dietary nutritional supplements, and its core products occupy a high market share; prescription drug business covers cardiovascular, anti-tumor, Digestive system, orthopedics, pediatrics, anti-infection and other treatment fields, it has the Xuesaitong Panax notoginseng series products, Shenfu injection, mitoxantrone hydrochloride injection for tracer, Huachansu tablets and injections, Yixuesheng Capsule , blood stasis, and sodium cefbiroster for injection have a high reputation in the medical end. In 2023, China Resources Sanjiu has 39 varieties with annual sales of over 100 million yuan, including "999 Cold Ling", "999 Dermatitis Ping", "Sanjiu Weitai", "999 Children's Cold Granules", and "999 Antiviral Oral Liquid ", "Qizhiwei Puer Granules", "Tianhe Gutong Tie Paste", "Yi Shanfu", "999 Aonuo Calcium Gluconate Zinc Oral Solution", "Xuesaitong Panax noto Series Products", "Kun Chinese Medicine Ginseng Lingjianpiwei Granules", "Afacalciferol Soft Capsules", "Sodium Hyaluronic Acid Injection" and so on have a leading position in related categories. The "999" brand enjoys high recognition in both the consumer and pharmaceutical industries. China Resources Sanjiu has always attached great importance to R&D and innovation. During the "14th Five-Year Plan" strategic period, China Resources Sanjiu will focus on the strategic direction, continue to increase R&D investment, improve the construction of innovation systems and mechanisms, and enhance innovation and development capabilities. While increasing the cooperation between industry, academia and research, three research institutes of innovative drugs, traditional Chinese medicine and health drugs have been established and operated one after another; innovative cooperation with Shenzhen Bay Laboratory has been carried out in depth, and clinical related to the QBH-196 project of anti-tumor innovative drug QBH-196 project has been vigorously promoted. Research. In 2023, R&D investment was 889 million yuan, and the proportion of new product R&D investment increased. There are a total of 112 projects under development, mainly focusing on anti-tumor, orthopedics, skin, respiratory, anti-infection and other treatment fields, and in new product project establishment, product R&D, and product strength. Positive progress has been made in areas such as improvement. China Resources Sanjiu attaches great importance to the inheritance and innovation of traditional Chinese medicine, continues to deepen the full-process development system of traditional Chinese medicine, precipitates the research and development capabilities of traditional Chinese medicine, and focuses on the research on classic prescriptions of traditional Chinese medicine, standards of traditional Chinese medicine formula granules and medicinal materials resources. The classic prescription embodies the essence of traditional Chinese medicine. The company adheres to the research idea of "inheriting the essence, keeping the truth and innovation", focuses on the elderly, women, and children, covering the treatment fields of breathing, heart and brain, digestion, etc., and carries out "Medicinal Materials-Decoction-Benchmark Sample- Systematic research on compound preparations, and build a traceability system for the entire industrial chain of traditional Chinese medicine. China Resources Sanjiu continues to pay attention to high-quality domestic and foreign resources, and makes strategic mergers and acquisitions integration efforts. Among them, China Resources Sanjiu and its holding subsidiary Kunzi Pharmaceutical Group have good synergy in terms of brands, products, channels, etc., and the business integration is progressing smoothly. We empower each other in the development of the Panax notoginseng industry and the creation of the "Kunzi Chinese Medicine 1381" brand. Coordinated development will promote Kunming Pharmaceutical Group to become the first healthy stock in silver economics. Against the backdrop of the ever-changing environment of the pharmaceutical industry, China Resources Sanjiu embraces industry and market development opportunities, leads "high-quality development" with innovation, adheres to the dual-wheel drive of "brand + innovation", and focuses on innovation and research and development of high-quality pharmaceutical and health products and intelligent manufacturing , optimize business layout, strengthen brand and channel construction, increase innovation investment, actively explore innovative development models of industrial chains, build competitive advantages of the entire industrial chain of traditional Chinese medicine, improve operational quality and efficiency, and achieve steady improvement in operating performance and core capabilities. During the "14th Five-Year Plan" strategic period, China Resources Sanjiu made solid progress on the road to becoming a leading enterprise in the industry, benchmarking against world-class enterprises, improving business layout, expanding its core business into the entire field of self-diagnosis and treatment, developing business focus on pipelines, and as the core Business empowerment to form a business model with "deep roots and lush leaves". Looking to the future, China Resources Sanjiu will always keep in mind its original mission and work hard to work hard. Under the mission of "caring for public health and creating a better life together", we will forge ahead to the goal of "leader of the mass medical and health industry" and serve Every member of the Chinese family.
China Resources Pharmaceutical Holdings Co., Ltd.
China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large state-owned pharmaceutical listed company, mainly engaged in the research and development, production, sales and related health services of pharmaceutical products. Up to now, China Resources Sanjiu has been included in the Shenzhen Component Index, CSI 500 and FTSE Russell Index. China Resources Sanjiu was predecessored by Shenzhen Southern Pharmaceutical Factory established in 1985. In 1999, five companies including Sanjiu Enterprise Group and Shenzhen Sanjiu Pharmaceutical Co., Ltd. initiated the establishment of joint-stock companies; on March 9, 2000, it was listed on the Shenzhen Stock Exchange (stock code is 000999); in 2008, Officially entered China Resources Group; in 2010, the company's name was changed from "Sanjiu Pharmaceutical Co., Ltd." to "China Resources Sanjiu Pharmaceutical Co., Ltd.". China Resources Sanjiu’s main core business is positioned in the fields of CHC health consumer goods and prescription drugs, with a rich product line and a continuous enrichment of varieties. CHC's health consumer products business covers nearly 10 categories including colds, skin, gastrointestinal tract, cough relieving, orthopedics, pediatrics, dietary nutritional supplements, and its core products occupy a high market share; prescription drug business covers cardiovascular, anti-tumor, Digestive system, orthopedics, pediatrics, anti-infection and other treatment fields, it has the Xuesaitong Panax notoginseng series products, Shenfu injection, mitoxantrone hydrochloride injection for tracer, Huachansu tablets and injections, Yixuesheng Capsule , blood stasis, and sodium cefbiroster for injection have a high reputation in the medical end. In 2023, China Resources Sanjiu has 39 varieties with annual sales of over 100 million yuan, including "999 Cold Ling", "999 Dermatitis Ping", "Sanjiu Weitai", "999 Children's Cold Granules", and "999 Antiviral Oral Liquid ", "Qizhiwei Puer Granules", "Tianhe Gutong Tie Paste", "Yi Shanfu", "999 Aonuo Calcium Gluconate Zinc Oral Solution", "Xuesaitong Panax noto Series Products", "Kun Chinese Medicine Ginseng Lingjianpiwei Granules", "Afacalciferol Soft Capsules", "Sodium Hyaluronic Acid Injection" and so on have a leading position in related categories. The "999" brand enjoys high recognition in both the consumer and pharmaceutical industries. China Resources Sanjiu has always attached great importance to R&D and innovation. During the "14th Five-Year Plan" strategic period, China Resources Sanjiu will focus on the strategic direction, continue to increase R&D investment, improve the construction of innovation systems and mechanisms, and enhance innovation and development capabilities. While increasing the cooperation between industry, academia and research, three research institutes of innovative drugs, traditional Chinese medicine and health drugs have been established and operated one after another; innovative cooperation with Shenzhen Bay Laboratory has been carried out in depth, and clinical related to the QBH-196 project of anti-tumor innovative drug QBH-196 project has been vigorously promoted. Research. In 2023, R&D investment was 889 million yuan, and the proportion of new product R&D investment increased. There are a total of 112 projects under development, mainly focusing on anti-tumor, orthopedics, skin, respiratory, anti-infection and other treatment fields, and in new product project establishment, product R&D, and product strength. Positive progress has been made in areas such as improvement. China Resources Sanjiu attaches great importance to the inheritance and innovation of traditional Chinese medicine, continues to deepen the full-process development system of traditional Chinese medicine, precipitates the research and development capabilities of traditional Chinese medicine, and focuses on the research on classic prescriptions of traditional Chinese medicine, standards of traditional Chinese medicine formula granules and medicinal materials resources. The classic prescription embodies the essence of traditional Chinese medicine. The company adheres to the research idea of "inheriting the essence, keeping the truth and innovation", focuses on the elderly, women, and children, covering the treatment fields of breathing, heart and brain, digestion, etc., and carries out "Medicinal Materials-Decoction-Benchmark Sample- Systematic research on compound preparations, and build a traceability system for the entire industrial chain of traditional Chinese medicine. China Resources Sanjiu continues to pay attention to high-quality domestic and foreign resources, and makes strategic mergers and acquisitions integration efforts. Among them, China Resources Sanjiu and its holding subsidiary Kunzi Pharmaceutical Group have good synergy in terms of brands, products, channels, etc., and the business integration is progressing smoothly. We empower each other in the development of the Panax notoginseng industry and the creation of the "Kunzi Chinese Medicine 1381" brand. Coordinated development will promote Kunming Pharmaceutical Group to become the first healthy stock in silver economics. Against the backdrop of the ever-changing environment of the pharmaceutical industry, China Resources Sanjiu embraces industry and market development opportunities, leads "high-quality development" with innovation, adheres to the dual-wheel drive of "brand + innovation", and focuses on innovation and research and development of high-quality pharmaceutical and health products and intelligent manufacturing , optimize business layout, strengthen brand and channel construction, increase innovation investment, actively explore innovative development models of industrial chains, build competitive advantages of the entire industrial chain of traditional Chinese medicine, improve operational quality and efficiency, and achieve steady improvement in operating performance and core capabilities. During the "14th Five-Year Plan" strategic period, China Resources Sanjiu made solid progress on the road to becoming a leading enterprise in the industry, benchmarking against world-class enterprises, improving business layout, expanding its core business into the entire field of self-diagnosis and treatment, developing business focus on pipelines, and as the core Business empowerment to form a business model with "deep roots and lush leaves". Looking to the future, China Resources Sanjiu will always keep in mind its original mission and work hard to work hard. Under the mission of "caring for public health and creating a better life together", we will forge ahead to the goal of "leader of the mass medical and health industry" and serve Every member of the Chinese family.
Nanjing Tongrentang Pharmaceutical Co., Ltd.
Tongrentang Pharmacy is a well-known old pharmacy in Beijing. Its predecessor was "Kyoto Tongrentang Lejia Old Shop". The reason why it is called "Lejia Old Shop" is because its founder's surname is Le, which is called Lezunyu. According to Ding Fengjun, the current chairman of Nanjing Tongrentang Pharmaceutical Co., Ltd., the predecessor of Nanjing Tongrentang Pharmaceutical Co., Ltd. was the Tongrentang Nanjing Branch. It was founded in 1926 and was ordered to be organized by Le Duzhou, the 13th generation of the Tongrentang Le family. Nanjing Tongrentang Pharmaceutical Co., Ltd. is located in the western foot of the beautiful Yuhuatai Scenic Area. It is a traditional Chinese medicine enterprise in Nanjing that produces traditional ancient recipes and comprehensive new dosage forms based on modern technology, integrating science, industry and trade. Nanjing Tongrentang Pharmaceutical Co., Ltd. has a long history. Its predecessor was the Nanjing branch of the Tongrentang Kyoto Lejia Old Shop in Beijing. It opened in 1926 and was renamed as the public-private joint venture Nanjing Tongrentang Sinopharm Co., Ltd. in 1955. It was named Nanjing Tongrentang in 1957. Pharmaceutical factory. In 1998, Nanjing Tongrentang Pharmaceutical Co., Ltd. was reorganized and established. In 2000, in accordance with the requirements of national industry management, the company invested huge amounts of money to transform GMP and introduced production lines for dosage forms such as tablets, pills, capsules, granules, oral liquids. In November 2002, nine dosage forms passed the national GMP certification in one go. The company continues to win the national "High-tech Enterprise" honor. In 2018, the company built a new factory in Nanjing Biomedical Valley, Pukou, with a significant improvement in the degree of production automation and accurate and controllable product quality, which accelerated the pace of enterprise scientific and technological development and greatly improved the technical content of Chinese patent medicines. While inheriting and carrying forward the traditional essence of Angong Niuhuang Pills, Niuhuang Qingxin Pills, Dahuolou Pills, Dendrobium Luminous Pills, Wuji Baifeng Pills, and Liuwei Dihuang Pills, the company has successively developed and developed a number of distinctive new products. In 2013, Nanjing Tongrentang deepened reforms, innovated marketing models, and completed the establishment of a professional sales team of more than 3,000 people in a short period of time. Data shows that from 2013 to 2018, the compound growth rate of Nanjing Tongrentang reached more than 70%.
Nanjing Tongrentang Pharmaceutical Co., Ltd.
Tongrentang Pharmacy is a well-known old pharmacy in Beijing. Its predecessor was "Kyoto Tongrentang Lejia Old Shop". The reason why it is called "Lejia Old Shop" is because its founder's surname is Le, which is called Lezunyu. According to Ding Fengjun, the current chairman of Nanjing Tongrentang Pharmaceutical Co., Ltd., the predecessor of Nanjing Tongrentang Pharmaceutical Co., Ltd. was the Tongrentang Nanjing Branch. It was founded in 1926 and was ordered to be organized by Le Duzhou, the 13th generation of the Tongrentang Le family. Nanjing Tongrentang Pharmaceutical Co., Ltd. is located in the western foot of the beautiful Yuhuatai Scenic Area. It is a traditional Chinese medicine enterprise in Nanjing that produces traditional ancient recipes and comprehensive new dosage forms based on modern technology, integrating science, industry and trade. Nanjing Tongrentang Pharmaceutical Co., Ltd. has a long history. Its predecessor was the Nanjing branch of the Tongrentang Kyoto Lejia Old Shop in Beijing. It opened in 1926 and was renamed as the public-private joint venture Nanjing Tongrentang Sinopharm Co., Ltd. in 1955. It was named Nanjing Tongrentang in 1957. Pharmaceutical factory. In 1998, Nanjing Tongrentang Pharmaceutical Co., Ltd. was reorganized and established. In 2000, in accordance with the requirements of national industry management, the company invested huge amounts of money to transform GMP and introduced production lines for dosage forms such as tablets, pills, capsules, granules, oral liquids. In November 2002, nine dosage forms passed the national GMP certification in one go. The company continues to win the national "High-tech Enterprise" honor. In 2018, the company built a new factory in Nanjing Biomedical Valley, Pukou, with a significant improvement in the degree of production automation and accurate and controllable product quality, which accelerated the pace of enterprise scientific and technological development and greatly improved the technical content of Chinese patent medicines. While inheriting and carrying forward the traditional essence of Angong Niuhuang Pills, Niuhuang Qingxin Pills, Dahuolou Pills, Dendrobium Luminous Pills, Wuji Baifeng Pills, and Liuwei Dihuang Pills, the company has successively developed and developed a number of distinctive new products. In 2013, Nanjing Tongrentang deepened reforms, innovated marketing models, and completed the establishment of a professional sales team of more than 3,000 people in a short period of time. Data shows that from 2013 to 2018, the compound growth rate of Nanjing Tongrentang reached more than 70%.
Shenwei Pharmaceutical Group Co., Ltd.
Shenwei Pharmaceutical Group is a large comprehensive enterprise group with the new Chinese medicine industry as its main business, and is listed on the main board of the Hong Kong Stock Exchange. Its main business covers Chinese medicinal materials cultivation, Chinese medicine preparations, Chinese medicine formula granules, Chinese herbal medicines, health products, and biopharmaceuticals. The upstream, midstream and downstream industrial chains have achieved full coverage of the new Chinese medicine industry from the field to the terminal, and are one of the large pharmaceutical enterprise groups with a relatively complete layout in the big health industry. Shenwei Pharmaceutical has formed special products such as modern Chinese medicine injections, modern Chinese medicine soft capsules, modern Chinese medicine granules, and Chinese medicine formula granules for the rapid growth of drugs for middle-aged and elderly people, children's medicine, antiviral drugs, and orthopedic drugs. Looking to the future, Shenwei Pharmaceutical will continue to deepen its development in the new Chinese medicine industry, continuously strengthen its professional academic marketing capabilities and precise brand management capabilities, and be the maker of modern Chinese medicine standards, the leader of modern Chinese medicine technology, and the guarantee of modern Chinese medicine quality. A demonstration of modern Chinese medicine innovation, leading modern Chinese medicine, promoting the health industry, and creating a century-old magical power.
Shenwei Pharmaceutical Group Co., Ltd.
Shenwei Pharmaceutical Group is a large comprehensive enterprise group with the new Chinese medicine industry as its main business, and is listed on the main board of the Hong Kong Stock Exchange. Its main business covers Chinese medicinal materials cultivation, Chinese medicine preparations, Chinese medicine formula granules, Chinese herbal medicines, health products, and biopharmaceuticals. The upstream, midstream and downstream industrial chains have achieved full coverage of the new Chinese medicine industry from the field to the terminal, and are one of the large pharmaceutical enterprise groups with a relatively complete layout in the big health industry. Shenwei Pharmaceutical has formed special products such as modern Chinese medicine injections, modern Chinese medicine soft capsules, modern Chinese medicine granules, and Chinese medicine formula granules for the rapid growth of drugs for middle-aged and elderly people, children's medicine, antiviral drugs, and orthopedic drugs. Looking to the future, Shenwei Pharmaceutical will continue to deepen its development in the new Chinese medicine industry, continuously strengthen its professional academic marketing capabilities and precise brand management capabilities, and be the maker of modern Chinese medicine standards, the leader of modern Chinese medicine technology, and the guarantee of modern Chinese medicine quality. A demonstration of modern Chinese medicine innovation, leading modern Chinese medicine, promoting the health industry, and creating a century-old magical power.
Sichuan Fengchun Pharmaceutical Co., Ltd.
Sichuan Fengchun Pharmaceutical Co., Ltd. (abbreviated as Fengchun/Fengchun Pharmaceutical) was founded in 1973 and completed its strategic restructuring in 2000 after the restructuring of the former Zhongjiang Pharmaceutical Factory. Now, a modern private enterprise has been formed that integrates pharmaceutical research, industrial production, pharmaceutical sales, agricultural breeding, big health industry, and project investment. As a long-standing pharmaceutical company in Kawachi, it has been devoted to inheriting the innovative development of traditional Chinese medicine and modern medicine. At present, it has 4 GMP production factories (including well-known subsidiaries such as Jiuzhaigou Natural Pharmaceutical and Sichuan Shenghe Pharmaceutical); more than 20 breeding companies; more than 5,000 employees; the company, wholly-owned subsidiaries and shareholders have assets of nearly 30 RMB 100 million; more than 1,500 mu of industrial land, with an industrial construction area of more than 330,000 square meters; more than 230,000 mu of GAP planting land, forestry and aquaculture land. In 2014, Fengchun acquired Jiuzhaigou Natural Pharmaceutical Co., Ltd. and its four wholly-owned subsidiaries; in early 2020, Fengchun Holdings Sichuan Shenghe Pharmaceutical Co., Ltd. and its two wholly-owned subsidiaries: 2021 Sichuan Fengchuntang Chinese Medicine Decoction Co., Ltd. was established in 2022 and passed the GMP certification, committed to creating Chinese medicine fine decoctions. At this point, Fengchun has taken solid steps in building a traditional Chinese and Western medicine industry with domestic first-class R&D capabilities, extremely large production scale and characteristics, as well as the Qiang and Tibetan ethnic pharmaceutical industries. At present, its pharmaceutical companies have 114 invention patents and 403 drug production approval documents. In order to sustainable protection and utilization of scarce traditional Chinese medicine resources, its Sichuan Fengchun Musk Industry Group has been established and approved 13 artificially bred forest musk and horse musk subsidiaries, and another 7 are under construction. Jiuzhaigou Natural Pharmaceutical Co., Ltd., a subsidiary, is one of more than 10 pharmaceutical companies approved to use natural musk in China recently, and is also a pharmaceutical company approved to use natural musk as a drug product in China.
Sichuan Fengchun Pharmaceutical Co., Ltd.
Sichuan Fengchun Pharmaceutical Co., Ltd. (abbreviated as Fengchun/Fengchun Pharmaceutical) was founded in 1973 and completed its strategic restructuring in 2000 after the restructuring of the former Zhongjiang Pharmaceutical Factory. Now, a modern private enterprise has been formed that integrates pharmaceutical research, industrial production, pharmaceutical sales, agricultural breeding, big health industry, and project investment. As a long-standing pharmaceutical company in Kawachi, it has been devoted to inheriting the innovative development of traditional Chinese medicine and modern medicine. At present, it has 4 GMP production factories (including well-known subsidiaries such as Jiuzhaigou Natural Pharmaceutical and Sichuan Shenghe Pharmaceutical); more than 20 breeding companies; more than 5,000 employees; the company, wholly-owned subsidiaries and shareholders have assets of nearly 30 RMB 100 million; more than 1,500 mu of industrial land, with an industrial construction area of more than 330,000 square meters; more than 230,000 mu of GAP planting land, forestry and aquaculture land. In 2014, Fengchun acquired Jiuzhaigou Natural Pharmaceutical Co., Ltd. and its four wholly-owned subsidiaries; in early 2020, Fengchun Holdings Sichuan Shenghe Pharmaceutical Co., Ltd. and its two wholly-owned subsidiaries: 2021 Sichuan Fengchuntang Chinese Medicine Decoction Co., Ltd. was established in 2022 and passed the GMP certification, committed to creating Chinese medicine fine decoctions. At this point, Fengchun has taken solid steps in building a traditional Chinese and Western medicine industry with domestic first-class R&D capabilities, extremely large production scale and characteristics, as well as the Qiang and Tibetan ethnic pharmaceutical industries. At present, its pharmaceutical companies have 114 invention patents and 403 drug production approval documents. In order to sustainable protection and utilization of scarce traditional Chinese medicine resources, its Sichuan Fengchun Musk Industry Group has been established and approved 13 artificially bred forest musk and horse musk subsidiaries, and another 7 are under construction. Jiuzhaigou Natural Pharmaceutical Co., Ltd., a subsidiary, is one of more than 10 pharmaceutical companies approved to use natural musk in China recently, and is also a pharmaceutical company approved to use natural musk as a drug product in China.
Hainan Calabash Kids Pharmaceutical Group Co., Ltd.
Guangxi Weiwei Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Huluwa Pharmaceutical Group. In November 2015, Huluwa Pharmaceutical Group successfully acquired 64 product approval documents and all sales networks of Nanning Weiwei Pharmaceutical Co., Ltd. and established Guangxi Weiwei Pharmaceutical Co., Ltd. In order to meet the market needs and better promote the modernization and standardization of traditional Chinese medicine, in 2016, Huluwa Pharmaceutical Group invested 250 million yuan in Nanning National Economic and Technological Development Zone to build the Nanning Production Base Project of the "Huluwa" brand series of medicines, and devoted its efforts to build the Nanning Production Base Project. Become the largest production base for children's Chinese patent medicines in China. The Nanning Production Base Project of the "Culuwa" brand series of medicines covers an area of about 48 mu. It started construction in November 2016, obtained the drug GMP certification in July 2018, and was put into production in August 2018. In 2020, Huluwa Pharmaceutical Group invested again 330 million yuan to build the second phase of Nanning production base project. The project uses about 41.78 mu of land and construction has started. The second phase of Huluwa Nanning Production Base project is another masterpiece of Huluwa Pharmaceutical Group for implementing the "China Children's Medicine National Brand Strategy", and is of great strategic significance for the group's future development and the expansion of the pharmaceutical industry scale of the Economic and Technological Development Zone. In addition, the group has also built a traditional Chinese medicine extract production base project in Laibin City, which is a supporting project of the Nanning production base. Guangxi Weiwei Pharmaceutical Co., Ltd. has always adhered to the corporate mission of "Healthy Chinese Babies" and has an intelligent production line, strictly implements the GMP quality assurance system to ensure excellent drug quality. At present, the company has 64 product approval documents, covering all provinces across the country. , municipal and county hospitals, chains, single pharmacies, etc. From the establishment of the factory to the present, Guangxi Weiwei has risen rapidly with a steady development speed and has grown into a benchmark enterprise in Guangxi's pharmaceutical industry. The company is built by Huluwa Pharmaceutical Group The production base of children's Chinese patent medicines carries the production and research and development of key products under the children's medicine brand in the future, laying a solid foundation for Huluwa Pharmaceutical Group to build the first brand of children's medicine in China. In the future, the foundation will be continuously consolidated and added We will strive to achieve high-quality development of enterprises and contribute greater strength to Nanning's economic construction.
Hainan Calabash Kids Pharmaceutical Group Co., Ltd.
Guangxi Weiwei Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Huluwa Pharmaceutical Group. In November 2015, Huluwa Pharmaceutical Group successfully acquired 64 product approval documents and all sales networks of Nanning Weiwei Pharmaceutical Co., Ltd. and established Guangxi Weiwei Pharmaceutical Co., Ltd. In order to meet the market needs and better promote the modernization and standardization of traditional Chinese medicine, in 2016, Huluwa Pharmaceutical Group invested 250 million yuan in Nanning National Economic and Technological Development Zone to build the Nanning Production Base Project of the "Huluwa" brand series of medicines, and devoted its efforts to build the Nanning Production Base Project. Become the largest production base for children's Chinese patent medicines in China. The Nanning Production Base Project of the "Culuwa" brand series of medicines covers an area of about 48 mu. It started construction in November 2016, obtained the drug GMP certification in July 2018, and was put into production in August 2018. In 2020, Huluwa Pharmaceutical Group invested again 330 million yuan to build the second phase of Nanning production base project. The project uses about 41.78 mu of land and construction has started. The second phase of Huluwa Nanning Production Base project is another masterpiece of Huluwa Pharmaceutical Group for implementing the "China Children's Medicine National Brand Strategy", and is of great strategic significance for the group's future development and the expansion of the pharmaceutical industry scale of the Economic and Technological Development Zone. In addition, the group has also built a traditional Chinese medicine extract production base project in Laibin City, which is a supporting project of the Nanning production base. Guangxi Weiwei Pharmaceutical Co., Ltd. has always adhered to the corporate mission of "Healthy Chinese Babies" and has an intelligent production line, strictly implements the GMP quality assurance system to ensure excellent drug quality. At present, the company has 64 product approval documents, covering all provinces across the country. , municipal and county hospitals, chains, single pharmacies, etc. From the establishment of the factory to the present, Guangxi Weiwei has risen rapidly with a steady development speed and has grown into a benchmark enterprise in Guangxi's pharmaceutical industry. The company is built by Huluwa Pharmaceutical Group The production base of children's Chinese patent medicines carries the production and research and development of key products under the children's medicine brand in the future, laying a solid foundation for Huluwa Pharmaceutical Group to build the first brand of children's medicine in China. In the future, the foundation will be continuously consolidated and added We will strive to achieve high-quality development of enterprises and contribute greater strength to Nanning's economic construction.
Chongqing Taiji Industry (Group) Co., Ltd.
Taiji Group Co., Ltd. (hereinafter referred to as "Taiji Group", stock code: 600129) was established in 1972 and completed its strategic restructuring in 2021, becoming a holding company of China Pharmaceutical Group Co., Ltd., the "Fortune 500" company. The company mainly focuses on intelligent manufacturing of modern Chinese medicine and supplemented by specialty chemical drugs. As an important part of the modern Chinese medicine sector of Sinopharm Group, it is committed to inheriting and innovating traditional Chinese medicine and developing modern medicine. It has 13 pharmaceutical factories and more than 20 pharmaceutical businesses. The company has more than 3,000 chain pharmacies with Sichuan and Chongqing as its main base, covering pharmaceutical research and development, pharmaceutical production, pharmaceutical commerce, Chinese medicinal materials resources and other fields, with 13,000 employees. In 1998, Taiji Group cooperated with many domestic and foreign institutions to establish a national postdoctoral workstation; in 1999, Taiji Group Technology Center was recognized as a National Enterprise Technology Center. In recent years, it has undertaken nearly 40 major special projects such as the Ministry of Science and Technology, the National Development and Reform Commission, and the Ministry of Industry and Information Technology, and more than 50 provincial projects. The company has successfully developed more than 40 new drugs, won more than 30 national new drug certificates, and won three Chinese patent gold medals. It has 300 valid authorized patents, a total of 1,240 drug approval documents, including 690 Chinese medicine varieties, 550 chemical medicine varieties, 739 medical insurance varieties, and 369 basic drugs. The company's products cover six major therapeutic areas, mainly including digestive system and metabolic drugs represented by Huoxiang Zhengqi Oral Liquid, Tailuo, etc., respiratory system drugs represented by acute syrup, and cardiovascular drugs represented by Salvia miltiorrhiza oral Liquid. , anti-infective drugs represented by Yibao Shiling, nervous system drugs represented by Tongtian Oral Liquid and Mefikang, anti-tumor and immunomodulatory drugs represented by paclitaxel, Bushen Yishou Capsules, etc., and Big Health Health products. The company's products have a high market share, and its brand and quality have won the recognition and trust of the people. Taiji Group will adhere to the corporate philosophy of "caring for life and caring for health", with the original mission of "Chinese Medicine Conservation in China, Taiji Helps the people", follow the goal positioning of "making the main business of medical and health stronger, better and bigger", and produce new sources, We will strive for excellence, continuously promote the modernization of traditional Chinese medicine, strive to build a world-class traditional Chinese medicine enterprise, promote traditional Chinese medicine to the world, and contribute the power of Chinese medicine Tai Chi to build a healthy China and realize the Chinese dream of the great rejuvenation of the Chinese nation.
Chongqing Taiji Industry (Group) Co., Ltd.
Taiji Group Co., Ltd. (hereinafter referred to as "Taiji Group", stock code: 600129) was established in 1972 and completed its strategic restructuring in 2021, becoming a holding company of China Pharmaceutical Group Co., Ltd., the "Fortune 500" company. The company mainly focuses on intelligent manufacturing of modern Chinese medicine and supplemented by specialty chemical drugs. As an important part of the modern Chinese medicine sector of Sinopharm Group, it is committed to inheriting and innovating traditional Chinese medicine and developing modern medicine. It has 13 pharmaceutical factories and more than 20 pharmaceutical businesses. The company has more than 3,000 chain pharmacies with Sichuan and Chongqing as its main base, covering pharmaceutical research and development, pharmaceutical production, pharmaceutical commerce, Chinese medicinal materials resources and other fields, with 13,000 employees. In 1998, Taiji Group cooperated with many domestic and foreign institutions to establish a national postdoctoral workstation; in 1999, Taiji Group Technology Center was recognized as a National Enterprise Technology Center. In recent years, it has undertaken nearly 40 major special projects such as the Ministry of Science and Technology, the National Development and Reform Commission, and the Ministry of Industry and Information Technology, and more than 50 provincial projects. The company has successfully developed more than 40 new drugs, won more than 30 national new drug certificates, and won three Chinese patent gold medals. It has 300 valid authorized patents, a total of 1,240 drug approval documents, including 690 Chinese medicine varieties, 550 chemical medicine varieties, 739 medical insurance varieties, and 369 basic drugs. The company's products cover six major therapeutic areas, mainly including digestive system and metabolic drugs represented by Huoxiang Zhengqi Oral Liquid, Tailuo, etc., respiratory system drugs represented by acute syrup, and cardiovascular drugs represented by Salvia miltiorrhiza oral Liquid. , anti-infective drugs represented by Yibao Shiling, nervous system drugs represented by Tongtian Oral Liquid and Mefikang, anti-tumor and immunomodulatory drugs represented by paclitaxel, Bushen Yishou Capsules, etc., and Big Health Health products. The company's products have a high market share, and its brand and quality have won the recognition and trust of the people. Taiji Group will adhere to the corporate philosophy of "caring for life and caring for health", with the original mission of "Chinese Medicine Conservation in China, Taiji Helps the people", follow the goal positioning of "making the main business of medical and health stronger, better and bigger", and produce new sources, We will strive for excellence, continuously promote the modernization of traditional Chinese medicine, strive to build a world-class traditional Chinese medicine enterprise, promote traditional Chinese medicine to the world, and contribute the power of Chinese medicine Tai Chi to build a healthy China and realize the Chinese dream of the great rejuvenation of the Chinese nation.
Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Guangzhou Xiangxue Pharmaceutical Co., Ltd. was established in 1997 and was listed on the Shenzhen Stock Exchange GEM in 2010 (stock code: 300147). The company regards the development of traditional Chinese medicine and the realization of traditional Chinese medicine modernization as its long-term development strategy. It has now become a leading Chinese medicine modernization enterprise and high-tech enterprise with independent intellectual property rights, independent brands and independent innovation capabilities, focusing on new Chinese herbal medicines, Chinese patent medicines, functional health products, The big health industry in the fields of biomedical engineering, life science research, etc. has successively established more than 60 subsidiaries in Guangdong, Beijing, Shanxi, Sichuan, Chongqing, Anhui, Yunnan and Ningxia, and invested in the construction of large-scale GMP production bases and GAPs. Medicinal materials planting bases will create a complete industrial chain of traditional Chinese medicine resource development, new drug research and development and creation, advanced traditional Chinese medicine manufacturing, and modern logistics and distribution, and form integrated innovation of the entire industrial chain.
Guangzhou Xiangxue Pharmaceutical Co., Ltd.
Guangzhou Xiangxue Pharmaceutical Co., Ltd. was established in 1997 and was listed on the Shenzhen Stock Exchange GEM in 2010 (stock code: 300147). The company regards the development of traditional Chinese medicine and the realization of traditional Chinese medicine modernization as its long-term development strategy. It has now become a leading Chinese medicine modernization enterprise and high-tech enterprise with independent intellectual property rights, independent brands and independent innovation capabilities, focusing on new Chinese herbal medicines, Chinese patent medicines, functional health products, The big health industry in the fields of biomedical engineering, life science research, etc. has successively established more than 60 subsidiaries in Guangdong, Beijing, Shanxi, Sichuan, Chongqing, Anhui, Yunnan and Ningxia, and invested in the construction of large-scale GMP production bases and GAPs. Medicinal materials planting bases will create a complete industrial chain of traditional Chinese medicine resource development, new drug research and development and creation, advanced traditional Chinese medicine manufacturing, and modern logistics and distribution, and form integrated innovation of the entire industrial chain.
Huatuo Chinese Medicine Co., Ltd.
Huatuo Sinopharm Co., Ltd. was founded in the 1950s and has a history of more than 60 years. It is located in the ancient capital of the Three Dynasties, the hometown of Huatuo, a famous historical and cultural city in China, and the first of the four major pharmaceutical capitals in the country - Bozhou City, Anhui Province . The company covers an area of 180,000 square meters, currently has more than 2,000 employees, has more than 100 approval documents for Sinopharm, and has built tablets, pills, capsules, granules, wine, liniment, pill drops, sprays, and health care. Ten production lines for food and Chinese herbal medicines. It is a modern enterprise integrating the production, operation and research and development of Chinese patent medicines. Under the jurisdiction: Huatuo National Pharmaceutical (Anhui) Pharmacy Co., Ltd., Huatuo National Pharmaceutical (Anhui) Health Wine Co., Ltd., Anhui Rare Hutu Wine Co., Ltd., Anhui Cao Cao Gong Wine Co., Ltd., and Anhui Huatuo Traditional Chinese Medicine R&D Center.
Huatuo Chinese Medicine Co., Ltd.
Huatuo Sinopharm Co., Ltd. was founded in the 1950s and has a history of more than 60 years. It is located in the ancient capital of the Three Dynasties, the hometown of Huatuo, a famous historical and cultural city in China, and the first of the four major pharmaceutical capitals in the country - Bozhou City, Anhui Province . The company covers an area of 180,000 square meters, currently has more than 2,000 employees, has more than 100 approval documents for Sinopharm, and has built tablets, pills, capsules, granules, wine, liniment, pill drops, sprays, and health care. Ten production lines for food and Chinese herbal medicines. It is a modern enterprise integrating the production, operation and research and development of Chinese patent medicines. Under the jurisdiction: Huatuo National Pharmaceutical (Anhui) Pharmacy Co., Ltd., Huatuo National Pharmaceutical (Anhui) Health Wine Co., Ltd., Anhui Rare Hutu Wine Co., Ltd., Anhui Cao Cao Gong Wine Co., Ltd., and Anhui Huatuo Traditional Chinese Medicine R&D Center.
Sinopharm Group Zhonglian Pharmaceutical Co., Ltd.
Sinopharm Zhonglian has a long history and is jointly formed by 199 traditional Chinese medicine stores represented by Ye Kaitai, Darentang, Liu Youyutang, Jin Tongren, Jiuzhitang, Chen Taiyi, etc., which have more than 400 years of traditional Chinese medicine history and are well-known throughout the country. In 1952, under the mobilization of the former Wuhan Traditional Chinese Medicine Decoction Industry Association, Wuhan Zhonglian Pharmaceutical Factory was established. In 1997, it was reorganized and reorganized at the end of 2011, China Pharmaceutical Group, a larger health industry platform in China, and in 2018, it entered the full-industry chain platform of China Pharmaceutical Group, China Pharmaceutical Holdings Co., Ltd. The company is committed to the development of the entire industrial chain of traditional Chinese medicine, and its main business covers classic traditional Chinese medicine production, Chinese herbal medicine planting and processing trade, Chinese herbal medicine tablets and formula granules and related intelligent distribution, Chinese medicine health industry, etc. The company has 334 registered products, currently 212 Chinese herbal medicines are being produced, and 455 varieties of formula granules have been registered, and has entered the provincial medical insurance catalog. The company's key products: Biejia Jianwan Pills, Jinye Baidu Granules, Jiawei Biochemical Granules and Xinnaoqing Soft Capsules are involved in the fields of liver medicine, respiratory medicine, gynecological medicine, and cardiovascular medicine. The company integrates seedling breeding, planting and primary processing of origin. Relying on Hubei Province's rich medicinal materials resources, it has created the main production area of "3+1" Hubei medicinal materials, covering 35 varieties bases, and the production area covers Qin. The Bashan, Wuling Mountain, Dabie Mountain and Jianghan Plain areas have currently settled in Yichang, Tianmen, Enshi, Huanggang and other places. The company fully utilizes the national brand advantages and technical product strength in the health field of "Sino Pharmaceutical Group" and "China Traditional Chinese Medicine" to carry out large-scale traditional Chinese medicine medical health services, and builds a Chinese medicine intelligent distribution center and a Chinese medicine diagnosis and treatment institution. After nearly 70 years of development and growth, the company has become a professional pharmaceutical and health enterprise integrating scientific research, production, circulation and foreign trade, and is a national high-tech enterprise. In the future, the company will focus on the development of its main business, open up the upstream and downstream of the entire traditional Chinese medicine chain, and steadily move towards the entire traditional Chinese medicine industry. Through 3-5 years of hard work and development, it will strive to become the leader in Hubei's traditional Chinese medicine industry.
Sinopharm Group Zhonglian Pharmaceutical Co., Ltd.
Sinopharm Zhonglian has a long history and is jointly formed by 199 traditional Chinese medicine stores represented by Ye Kaitai, Darentang, Liu Youyutang, Jin Tongren, Jiuzhitang, Chen Taiyi, etc., which have more than 400 years of traditional Chinese medicine history and are well-known throughout the country. In 1952, under the mobilization of the former Wuhan Traditional Chinese Medicine Decoction Industry Association, Wuhan Zhonglian Pharmaceutical Factory was established. In 1997, it was reorganized and reorganized at the end of 2011, China Pharmaceutical Group, a larger health industry platform in China, and in 2018, it entered the full-industry chain platform of China Pharmaceutical Group, China Pharmaceutical Holdings Co., Ltd. The company is committed to the development of the entire industrial chain of traditional Chinese medicine, and its main business covers classic traditional Chinese medicine production, Chinese herbal medicine planting and processing trade, Chinese herbal medicine tablets and formula granules and related intelligent distribution, Chinese medicine health industry, etc. The company has 334 registered products, currently 212 Chinese herbal medicines are being produced, and 455 varieties of formula granules have been registered, and has entered the provincial medical insurance catalog. The company's key products: Biejia Jianwan Pills, Jinye Baidu Granules, Jiawei Biochemical Granules and Xinnaoqing Soft Capsules are involved in the fields of liver medicine, respiratory medicine, gynecological medicine, and cardiovascular medicine. The company integrates seedling breeding, planting and primary processing of origin. Relying on Hubei Province's rich medicinal materials resources, it has created the main production area of "3+1" Hubei medicinal materials, covering 35 varieties bases, and the production area covers Qin. The Bashan, Wuling Mountain, Dabie Mountain and Jianghan Plain areas have currently settled in Yichang, Tianmen, Enshi, Huanggang and other places. The company fully utilizes the national brand advantages and technical product strength in the health field of "Sino Pharmaceutical Group" and "China Traditional Chinese Medicine" to carry out large-scale traditional Chinese medicine medical health services, and builds a Chinese medicine intelligent distribution center and a Chinese medicine diagnosis and treatment institution. After nearly 70 years of development and growth, the company has become a professional pharmaceutical and health enterprise integrating scientific research, production, circulation and foreign trade, and is a national high-tech enterprise. In the future, the company will focus on the development of its main business, open up the upstream and downstream of the entire traditional Chinese medicine chain, and steadily move towards the entire traditional Chinese medicine industry. Through 3-5 years of hard work and development, it will strive to become the leader in Hubei's traditional Chinese medicine industry.
Sichuan Yike Pharmaceutical Co., Ltd.
Sichuan Yike Pharmaceutical Co., Ltd. is a high-tech international enterprise with the big health industry as its main line, the biopharmaceutical industry as its core, and the health industry and medical rehabilitation, health care and health management as its wings. There are more than ten subsidiaries, and have established academician and expert workstations, postdoctoral innovation practice bases and enterprise R&D centers. The group has China's advanced Chinese medicine extraction and preparation production capabilities, and has the ability to produce varieties such as medicine and food, health food, and health tablets. The group has formed a modern pharmaceutical industry chain that integrates all aspects of drug research and development, medicinal material planting, Chinese medicine extraction, preparation production and marketing, and has developed and cultivated a group of traditional Chinese and Western medicine products with accurate efficacy and high market reputation, among which the most Representative Ammonia Huangmin Capsules, Gake Compound Aminophen Alkylamine Capsules, Aminophen Namin Granules, Pediatric Aminophen Huangnamin Granules, Amoxicillin Capsules, Multi-enzyme Tablets, Huoxiang Zhengqi Water, Compound Salvia Squid Sinensis Tablets, A series of Chinese and Western medicines such as isatis root granules, Jingxueguanxin granules, Tongmai granules, Tongxuanlifei granules, etc. are highly recognized by consumers. Looking to the future, the Group will vigorously integrate resources and promote the strategy of strengthening talents and managing innovation under the guidance of "sophisticated, meticulous and strict learning, understanding the changes of the situation, specializing in new ideas, and inheriting culture". Medicine is our responsibility, with a scientific, rigorous and responsible attitude, we wholeheartedly create healthy life for the people, and strive to strive for the goals of China's advanced pharmaceutical companies.
Sichuan Yike Pharmaceutical Co., Ltd.
Sichuan Yike Pharmaceutical Co., Ltd. is a high-tech international enterprise with the big health industry as its main line, the biopharmaceutical industry as its core, and the health industry and medical rehabilitation, health care and health management as its wings. There are more than ten subsidiaries, and have established academician and expert workstations, postdoctoral innovation practice bases and enterprise R&D centers. The group has China's advanced Chinese medicine extraction and preparation production capabilities, and has the ability to produce varieties such as medicine and food, health food, and health tablets. The group has formed a modern pharmaceutical industry chain that integrates all aspects of drug research and development, medicinal material planting, Chinese medicine extraction, preparation production and marketing, and has developed and cultivated a group of traditional Chinese and Western medicine products with accurate efficacy and high market reputation, among which the most Representative Ammonia Huangmin Capsules, Gake Compound Aminophen Alkylamine Capsules, Aminophen Namin Granules, Pediatric Aminophen Huangnamin Granules, Amoxicillin Capsules, Multi-enzyme Tablets, Huoxiang Zhengqi Water, Compound Salvia Squid Sinensis Tablets, A series of Chinese and Western medicines such as isatis root granules, Jingxueguanxin granules, Tongmai granules, Tongxuanlifei granules, etc. are highly recognized by consumers. Looking to the future, the Group will vigorously integrate resources and promote the strategy of strengthening talents and managing innovation under the guidance of "sophisticated, meticulous and strict learning, understanding the changes of the situation, specializing in new ideas, and inheriting culture". Medicine is our responsibility, with a scientific, rigorous and responsible attitude, we wholeheartedly create healthy life for the people, and strive to strive for the goals of China's advanced pharmaceutical companies.
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Guangzhou Baiyunshan Hutchison Huangpu Traditional Chinese Medicine Co., Ltd. (hereinafter referred to as "Baiyunshan Hutchison Huangpu") was jointly established in May 2005 by the Baiyunshan Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Group and Hutchison Huangpu (China) Company, a subsidiary of Mr. Li Ka-shing. The joint venture was formerly known as Guangzhou Baiyunshan Traditional Chinese Medicine Factory. It was established in May 1988. It was derived from the farm operation area established in 1956 and was transformed into a tonic factory that combines agriculture and industry, and then transformed into Guangzhou Baiyun, which operates the pharmaceutical and health industry. Shan Chinese Medicine Factory. The company stands at the forefront of the times and the height of the industry, takes the cross policy of "education, love, technology, innovation, responsibility" as a guide, and takes the mission of "modernization of traditional Chinese medicine, internationalization of traditional Chinese medicine, popularization of traditional Chinese medicine, and popularization of traditional Chinese medicine" as its mission, and takes economic benefits. As the center, we focus on management internally, expand the market externally, and implement the three major strategies of "talent, brand, and technology", forming five core competitive advantages: scientific and technological innovation, responsible marketing, cultural heritage, talent engineering, and advanced party building. Especially since 1999, the company has entered a period of rapid growth and achieved leapfrog development. From 1999 to 2013, the scale of the enterprise expanded by 30 times, and the four indicators of sales, collection, output value and profit maintained a growth of more than 30%. The company actively builds a pioneer modern Chinese medicine enterprise and enters into advantageous enterprises in the big health industry.
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Guangzhou Baiyunshan Hutchison Huangpu Traditional Chinese Medicine Co., Ltd. (hereinafter referred to as "Baiyunshan Hutchison Huangpu") was jointly established in May 2005 by the Baiyunshan Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Group and Hutchison Huangpu (China) Company, a subsidiary of Mr. Li Ka-shing. The joint venture was formerly known as Guangzhou Baiyunshan Traditional Chinese Medicine Factory. It was established in May 1988. It was derived from the farm operation area established in 1956 and was transformed into a tonic factory that combines agriculture and industry, and then transformed into Guangzhou Baiyun, which operates the pharmaceutical and health industry. Shan Chinese Medicine Factory. The company stands at the forefront of the times and the height of the industry, takes the cross policy of "education, love, technology, innovation, responsibility" as a guide, and takes the mission of "modernization of traditional Chinese medicine, internationalization of traditional Chinese medicine, popularization of traditional Chinese medicine, and popularization of traditional Chinese medicine" as its mission, and takes economic benefits. As the center, we focus on management internally, expand the market externally, and implement the three major strategies of "talent, brand, and technology", forming five core competitive advantages: scientific and technological innovation, responsible marketing, cultural heritage, talent engineering, and advanced party building. Especially since 1999, the company has entered a period of rapid growth and achieved leapfrog development. From 1999 to 2013, the scale of the enterprise expanded by 30 times, and the four indicators of sales, collection, output value and profit maintained a growth of more than 30%. The company actively builds a pioneer modern Chinese medicine enterprise and enters into advantageous enterprises in the big health industry.
Sichuan Rainbow Pharmaceutical Co., Ltd.
Sichuan Rainbow Pharmaceutical Co., Ltd. was established on October 9, 1998. The legal representative is Wu Xiaohong. In 2009, Sichuan Rainbow Pharmaceutical Co., Ltd. added 83.67 mu of land in Qingshen County Industrial Development Zone, Meishan City, and invested 70 million yuan to build new factory buildings and facilities. , equipment, solid preparation workshop, liquid preparation workshop, warehouse, office building, inspection building, seven purification production lines including tablets, capsules, granules, and designed production capacity of 200 million yuan; it is a company that is strictly designed and built in accordance with the standardized "GMP" A modern pharmaceutical company that has passed the new version of GMP certification. 1. Basic information of the company The company's registered capital is 50.25 million yuan, covering an area of 83.67 mu, a total factory area of 24748.86 square meters, total assets are more than 90 million yuan, and more than 50 varieties and specifications. In August 2016, it merged Chengdu Jule Pharmaceutical Co., Ltd. as a whole and added Jule Nine varieties of Shugan Tablets under Le's name have been successfully transferred to the company. Now they have registered more than 350 employees, more than 500 units (sets), and achieved sales revenue of 120 million yuan. 2. Company honors and brand building The company's Shenchai Capsules, Huoka, Xiangzhengqi Water, compound isatis root granules, compound Yinqiao Capsules, etc. are sold in more than 20 provinces and cities across the country. The finished products have established the Rainbow’s “Kangsen” brand effect in China, and have unique advantages among similar manufacturers and have strong market competitiveness. Since the registration of the "Kangsen" trademark, the company has paid special attention to product quality and has achieved no quality and safety accidents or public quality recruitment in the past three years. The company has established extensive academic connections with Sichuan University West China Medical College and Chengdu University of Traditional Chinese Medicine, ensuring the advanced and authoritative technology. At present, the company's Shenchai Capsule Flow Extract and Traditional Chinese Medicine Extraction Heat Reflux Technology and the innovative technology of compound Yinjingammonic Capsules are among the cutting-edge technologies in the domestic industry. 3. Company sales and network construction 1. In terms of market sales and sales network construction, the company has established offices and sales networks in fifteen provinces through ten years, and has sold more than 20 provinces. 2. OTC sales are the company's focus on building and construction. In terms of product positioning, the company positions the entire packaging in a mid-to-high-end position and sets the unit price in a mid-range position. Build a brand in a variety of different ways. With the expectation of increasing prices and increasing added value, an OTC team mainly consisting of Sichuan and Chongqing and covering the national market positioning has been established, with a total of 200 people engaged in it. 4. Foreign investment enterprises Sichuan Rainbow Pharmaceutical Co., Ltd. invested 3 million yuan in 2008 to establish Sichuan Hongsheng Pharmaceutical Packaging Co., Ltd., covering an area of 10 acres. It has two types of medicine packaging materials, namely oral solid medicinal polypropylene bottles and oral liquid medicinal high-density polyethylene bottles. It is certified to produce about 50 bottle types including 10ml, 20ml, 30ml, 40ml, 60ml, 80ml, 100ml, 150ml, 300ml, etc. From the purchase of raw materials to the factory, it is strictly produced and standardized in accordance with GMP requirements. In 2013, Sichuan Hongsheng Pharmaceutical Packaging Co., Ltd. purchased a newly fully automatic grinding and injection molding machine with an output value of 6 million yuan. Sichuan Yuetong Pharmaceutical Co., Ltd. was established in 2010 and is a newly established commercial company that the company has wholly owned.
Sichuan Rainbow Pharmaceutical Co., Ltd.
Sichuan Rainbow Pharmaceutical Co., Ltd. was established on October 9, 1998. The legal representative is Wu Xiaohong. In 2009, Sichuan Rainbow Pharmaceutical Co., Ltd. added 83.67 mu of land in Qingshen County Industrial Development Zone, Meishan City, and invested 70 million yuan to build new factory buildings and facilities. , equipment, solid preparation workshop, liquid preparation workshop, warehouse, office building, inspection building, seven purification production lines including tablets, capsules, granules, and designed production capacity of 200 million yuan; it is a company that is strictly designed and built in accordance with the standardized "GMP" A modern pharmaceutical company that has passed the new version of GMP certification. 1. Basic information of the company The company's registered capital is 50.25 million yuan, covering an area of 83.67 mu, a total factory area of 24748.86 square meters, total assets are more than 90 million yuan, and more than 50 varieties and specifications. In August 2016, it merged Chengdu Jule Pharmaceutical Co., Ltd. as a whole and added Jule Nine varieties of Shugan Tablets under Le's name have been successfully transferred to the company. Now they have registered more than 350 employees, more than 500 units (sets), and achieved sales revenue of 120 million yuan. 2. Company honors and brand building The company's Shenchai Capsules, Huoka, Xiangzhengqi Water, compound isatis root granules, compound Yinqiao Capsules, etc. are sold in more than 20 provinces and cities across the country. The finished products have established the Rainbow’s “Kangsen” brand effect in China, and have unique advantages among similar manufacturers and have strong market competitiveness. Since the registration of the "Kangsen" trademark, the company has paid special attention to product quality and has achieved no quality and safety accidents or public quality recruitment in the past three years. The company has established extensive academic connections with Sichuan University West China Medical College and Chengdu University of Traditional Chinese Medicine, ensuring the advanced and authoritative technology. At present, the company's Shenchai Capsule Flow Extract and Traditional Chinese Medicine Extraction Heat Reflux Technology and the innovative technology of compound Yinjingammonic Capsules are among the cutting-edge technologies in the domestic industry. 3. Company sales and network construction 1. In terms of market sales and sales network construction, the company has established offices and sales networks in fifteen provinces through ten years, and has sold more than 20 provinces. 2. OTC sales are the company's focus on building and construction. In terms of product positioning, the company positions the entire packaging in a mid-to-high-end position and sets the unit price in a mid-range position. Build a brand in a variety of different ways. With the expectation of increasing prices and increasing added value, an OTC team mainly consisting of Sichuan and Chongqing and covering the national market positioning has been established, with a total of 200 people engaged in it. 4. Foreign investment enterprises Sichuan Rainbow Pharmaceutical Co., Ltd. invested 3 million yuan in 2008 to establish Sichuan Hongsheng Pharmaceutical Packaging Co., Ltd., covering an area of 10 acres. It has two types of medicine packaging materials, namely oral solid medicinal polypropylene bottles and oral liquid medicinal high-density polyethylene bottles. It is certified to produce about 50 bottle types including 10ml, 20ml, 30ml, 40ml, 60ml, 80ml, 100ml, 150ml, 300ml, etc. From the purchase of raw materials to the factory, it is strictly produced and standardized in accordance with GMP requirements. In 2013, Sichuan Hongsheng Pharmaceutical Packaging Co., Ltd. purchased a newly fully automatic grinding and injection molding machine with an output value of 6 million yuan. Sichuan Yuetong Pharmaceutical Co., Ltd. was established in 2010 and is a newly established commercial company that the company has wholly owned.
Guangzhou Nuojin Pharmaceutical Co., Ltd.
Guangzhou Nuojin Pharmaceutical Co., Ltd. is located in Guangzhou Economic and Technological Development Zone. The company was established in July 2003. It is a modern enterprise integrating R&D, production and sales. The company covers an area of 40,000 square meters, and its products are mainly oral preparations of Chinese patent medicines. Currently, it has a high-quality preparation production line of various national GMP certified by GMP products, including tablets, hard capsules, granules, pills, glues, traditional Chinese medicine pretreatment and extraction. And by establishing a five-level quality management system of "raw material supply, enterprise decision-making level, quality policy implementation department, production operation front line, drug after-sales service", we vigorously carry out quality management activities for all employees to comprehensively ensure product quality. The company adheres to the business philosophy of "reputation first and quality first". With a solid quality foundation, it has formed a healthy and close cooperative relationship with retail and wholesale companies across the country, including lily solid gold tablets, wet toxin clearing tablets, compound honeysuckle granules, etc. The flagship products have been sold well across the country. At the same time, the new series of Nuojintang Pills, which mainly produces classic prescriptions for all ages, has been launched on the market, which will inject new vitality into the traditional Chinese pill market. The company also continues to carry out various forms of marketing activities and brand promotion activities, participate in social activities, and continuously fulfill the company's social responsibilities. In the future, Guangzhou Nuojin Pharmaceutical Co., Ltd. will continue to improve product quality and broaden the sales network layout, and strive to develop Guangzhou Nuojin Pharmaceutical Co., Ltd. into a modernization with Chinese patent medicine and R&D as its main business, integrating standardized planting of medicinal materials. High-tech pharmaceutical company.
Guangzhou Nuojin Pharmaceutical Co., Ltd.
Guangzhou Nuojin Pharmaceutical Co., Ltd. is located in Guangzhou Economic and Technological Development Zone. The company was established in July 2003. It is a modern enterprise integrating R&D, production and sales. The company covers an area of 40,000 square meters, and its products are mainly oral preparations of Chinese patent medicines. Currently, it has a high-quality preparation production line of various national GMP certified by GMP products, including tablets, hard capsules, granules, pills, glues, traditional Chinese medicine pretreatment and extraction. And by establishing a five-level quality management system of "raw material supply, enterprise decision-making level, quality policy implementation department, production operation front line, drug after-sales service", we vigorously carry out quality management activities for all employees to comprehensively ensure product quality. The company adheres to the business philosophy of "reputation first and quality first". With a solid quality foundation, it has formed a healthy and close cooperative relationship with retail and wholesale companies across the country, including lily solid gold tablets, wet toxin clearing tablets, compound honeysuckle granules, etc. The flagship products have been sold well across the country. At the same time, the new series of Nuojintang Pills, which mainly produces classic prescriptions for all ages, has been launched on the market, which will inject new vitality into the traditional Chinese pill market. The company also continues to carry out various forms of marketing activities and brand promotion activities, participate in social activities, and continuously fulfill the company's social responsibilities. In the future, Guangzhou Nuojin Pharmaceutical Co., Ltd. will continue to improve product quality and broaden the sales network layout, and strive to develop Guangzhou Nuojin Pharmaceutical Co., Ltd. into a modernization with Chinese patent medicine and R&D as its main business, integrating standardized planting of medicinal materials. High-tech pharmaceutical company.
Lishizhen Medical Group Co., Ltd.
Li Shizhen Pharmaceutical Group was officially established in 2002. It is located in Qichun, Hubei, the hometown of the Medical Saint Li Shizhen. It has now developed into a series of major health products such as the cultivation of authentic medicinal materials, Chinese patent medicines, Chinese herbal medicine tablets, Chinese herbal formula granules, health wine, Qi Ai series of big health products A full-industry chain group company integrating production, R&D, pharmaceutical wholesale and retail, pharmaceutical culture and tourism, moxibustion, massage and other traditional Chinese medicine suitable technical training. The group is a high-tech enterprise in Hubei Province, a pharmaceutical GMP inspector training base in Hubei Province, a college graduate employment internship base in Hubei Province, and a graduate work station in Central China Agricultural University. The group has two major production bases, "Hubei Qichun Compendium Materia Medica Biotechnology Park", "Xiamen Meishang Pharmaceutical Haicang Factory Area", and "Hubei Wuhan Taiwan Biotechnology Industrial Park" (Medical Flow Park), with 8 holding subsidiaries. , has 20 pharmaceutical production dosage forms, 185 national drug approval documents, 23 dosage forms and production license items that have passed the national GMP certification, 22 production workshops, a factory area of 150,000 square meters, and an annual production capacity of 6 billion yuan. Now, more than 100 Chinese patent medicine varieties are mainly produced, of which more than 40 basic medicine varieties can be included in the medical insurance catalog; more than 350 Chinese medicine formula granules are produced; more than 700 authentic Chinese herbal medicine varieties are produced and operated, and more than 100 Qi Ai products are produced. The group takes the Hubei Provincial Traditional Chinese Medicine Resource Application Engineering Technology Research Center awarded by the Hubei Provincial Department of Science and Technology as an innovative research and development platform, and has joined hands with 15 domestic scientific research institutes and universities to carry out extensive cooperation in industry, academia and research to build the company's high-level scientific research platform. There are currently 7 major laboratories, equipped with more than 200 sets of various scientific research facilities and equipment, and nearly 100 technical support personnel engaged in scientific research and R&D. They can conduct trial production of products such as medicines, food, cosmetics, disinfection products, medical devices, and wormwood products. There are more than 1,100 standard formulation, stability inspection and performance testing projects, and a series of scientific research work such as trace detection, molecular structure confirmation, bactericidal ability confirmation, trace element and content analysis and detection can also be carried out. More than 50 million yuan of R&D expenses are invested every year, nearly 10 national and provincial scientific research projects have been approved, more than 30 patents have been obtained, and 8 provincial and municipal scientific and technological progress awards have been won. The developed traditional Chinese medicine formula granules have been included in the production pilot project by Hubei Province. The group has established more than 800 terminal marketing service offices, with sales networks all over the country. The group owns brands such as "Compendium of Materia Medica", "Li Shizhen", "Qi Ai" and "Jia Fang". The group established the production concept of "using authentic medicinal materials and making scientific Chinese medicine", and always regarded the fields as the production workshop of the enterprise, standardized the entire production process from the source, strictly abide by the GAP standards, and established Coptis chinensis, Magnolia officinalis, Sydney, Sichuan shellfish, There are more than 100 mu of authentic medicinal materials bases of more than 100 varieties of Qi Ai and Xia Dust Grass.
Lishizhen Medical Group Co., Ltd.
Li Shizhen Pharmaceutical Group was officially established in 2002. It is located in Qichun, Hubei, the hometown of the Medical Saint Li Shizhen. It has now developed into a series of major health products such as the cultivation of authentic medicinal materials, Chinese patent medicines, Chinese herbal medicine tablets, Chinese herbal formula granules, health wine, Qi Ai series of big health products A full-industry chain group company integrating production, R&D, pharmaceutical wholesale and retail, pharmaceutical culture and tourism, moxibustion, massage and other traditional Chinese medicine suitable technical training. The group is a high-tech enterprise in Hubei Province, a pharmaceutical GMP inspector training base in Hubei Province, a college graduate employment internship base in Hubei Province, and a graduate work station in Central China Agricultural University. The group has two major production bases, "Hubei Qichun Compendium Materia Medica Biotechnology Park", "Xiamen Meishang Pharmaceutical Haicang Factory Area", and "Hubei Wuhan Taiwan Biotechnology Industrial Park" (Medical Flow Park), with 8 holding subsidiaries. , has 20 pharmaceutical production dosage forms, 185 national drug approval documents, 23 dosage forms and production license items that have passed the national GMP certification, 22 production workshops, a factory area of 150,000 square meters, and an annual production capacity of 6 billion yuan. Now, more than 100 Chinese patent medicine varieties are mainly produced, of which more than 40 basic medicine varieties can be included in the medical insurance catalog; more than 350 Chinese medicine formula granules are produced; more than 700 authentic Chinese herbal medicine varieties are produced and operated, and more than 100 Qi Ai products are produced. The group takes the Hubei Provincial Traditional Chinese Medicine Resource Application Engineering Technology Research Center awarded by the Hubei Provincial Department of Science and Technology as an innovative research and development platform, and has joined hands with 15 domestic scientific research institutes and universities to carry out extensive cooperation in industry, academia and research to build the company's high-level scientific research platform. There are currently 7 major laboratories, equipped with more than 200 sets of various scientific research facilities and equipment, and nearly 100 technical support personnel engaged in scientific research and R&D. They can conduct trial production of products such as medicines, food, cosmetics, disinfection products, medical devices, and wormwood products. There are more than 1,100 standard formulation, stability inspection and performance testing projects, and a series of scientific research work such as trace detection, molecular structure confirmation, bactericidal ability confirmation, trace element and content analysis and detection can also be carried out. More than 50 million yuan of R&D expenses are invested every year, nearly 10 national and provincial scientific research projects have been approved, more than 30 patents have been obtained, and 8 provincial and municipal scientific and technological progress awards have been won. The developed traditional Chinese medicine formula granules have been included in the production pilot project by Hubei Province. The group has established more than 800 terminal marketing service offices, with sales networks all over the country. The group owns brands such as "Compendium of Materia Medica", "Li Shizhen", "Qi Ai" and "Jia Fang". The group established the production concept of "using authentic medicinal materials and making scientific Chinese medicine", and always regarded the fields as the production workshop of the enterprise, standardized the entire production process from the source, strictly abide by the GAP standards, and established Coptis chinensis, Magnolia officinalis, Sydney, Sichuan shellfish, There are more than 100 mu of authentic medicinal materials bases of more than 100 varieties of Qi Ai and Xia Dust Grass.
Zhongzhi Pharmaceutical Group Co., Ltd., Zhongshan
Zhongzhi Pharmaceutical Group is an innovative traditional Chinese medicine enterprise and a broken wall decoction manufacturer in Guangdong Province. It is the inventor of the technology of broken wall decoction and the pioneer of the new health herbal medicine category. The group was listed on the main board of the Hong Kong Stock Exchange in July 2015 (China Zhi Pharmaceutical: 03737.HK), and is headquartered in Zhongshan, a hub city in the Guangdong-Hong Kong-Macao Greater Bay Area. Since its establishment in 1993, China Zhi Pharmaceutical Group has developed into an innovative enterprise integrating new Chinese herbal medicines, Chinese patent medicines and health food scientific research, production, sales, and pharmaceutical retail chains. Zhongzhi Pharmaceutical Group owns brands such as "Zhongzhi" and "Cao Jinghua", has established 44 Chinese medicine ecological traceability planting bases, 10 subsidiaries, and has a complete pharmaceutical production and operation industry chain.
Zhongzhi Pharmaceutical Group Co., Ltd., Zhongshan
Zhongzhi Pharmaceutical Group is an innovative traditional Chinese medicine enterprise and a broken wall decoction manufacturer in Guangdong Province. It is the inventor of the technology of broken wall decoction and the pioneer of the new health herbal medicine category. The group was listed on the main board of the Hong Kong Stock Exchange in July 2015 (China Zhi Pharmaceutical: 03737.HK), and is headquartered in Zhongshan, a hub city in the Guangdong-Hong Kong-Macao Greater Bay Area. Since its establishment in 1993, China Zhi Pharmaceutical Group has developed into an innovative enterprise integrating new Chinese herbal medicines, Chinese patent medicines and health food scientific research, production, sales, and pharmaceutical retail chains. Zhongzhi Pharmaceutical Group owns brands such as "Zhongzhi" and "Cao Jinghua", has established 44 Chinese medicine ecological traceability planting bases, 10 subsidiaries, and has a complete pharmaceutical production and operation industry chain.
Shanxi Zhendong Pharmaceutical Co., Ltd.
A modern brand integrating traditional Chinese medicine with advanced technology to produce high-quality Banlangen.
Shanxi Zhendong Pharmaceutical Co., Ltd.
A modern brand integrating traditional Chinese medicine with advanced technology to produce high-quality Banlangen.
Beijing Tongrentang Co., Ltd.
A historic brand offering Banlangen products, renowned for its adherence to traditional Chinese medicine practices.
Beijing Tongrentang Co., Ltd.
A historic brand offering Banlangen products, renowned for its adherence to traditional Chinese medicine practices.
